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Abstract
Background: Anaemia is a common clinical finding in HIV infected women and has been associated with advanced disease.
The use of antiretroviral drugs such as Zidovudine (ZDV) either for prevention of mother to child transmission (MTCT) of HIV
or used in combination with other antiretrovirals have been implicated in the development or increased severity of
anaemia. We report the prevalence, type, severity and incidence of anaemia in a cohort of HIV infected women who
initiated antiretroviral prophylaxis or treatment during pregnancy.
Methods and Materials: This is a retrospective cohort data analysis of 408 HIV infected pregnant women who participated
in a breastfeeding intervention study (HPTN 046 Study, ClinicalTrials.gov NCT 00074412) in South Africa. Women initiated
zidovudine prophylaxis for PMTCT or triple antiretroviral treatment in pregnancy according to the standard of care.
Laboratory and clinical data in pregnancy, ,72 hours and 2 weeks postdelivery were extracted from the main database and
analysed.
Results: The mean Hb concentration was 10.6 g/dL at baseline and 262/408 (64.2%) women were diagnosed with anaemia
(Hb,11 g/dL) in pregnancy, 48/146 (32.9%) subsequently developed anaemia intrapartum or postpartum and 89/310
(28.7%) of all cases of anaemia remained unresolved by 2 weeks postdelivery. In a univariate analysis, CD4 count and
gravidity were significant risk factors for anaemia in pregnancy, RR 1.41; 1.23–1.61 (p,0.001) and 1.10; 1.01–1.18 (p = 0.02)
respectively. After adjusting for antiretroviral regimen, age and gravidity in a multivariable analysis, only the CD4 count
remains a significant risk factor for anaemia in pregnancy and postdelivery.
Conclusion: In conclusion, anaemia was most common among women in the advanced stage of HIV infection (CD4,200
cells/mm3). There was no evidence of an association between ZDV or triple ARVs and anaemia.
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Introduction
The World Health Organization estimates that nearly half of all
women in low resource countries have anaemia (52%) [1]. Women
of reproductive age (15–49 years) are most commonly affected and
likely due to excessive blood loss during menstruation, insufficient
dietary intake, parasitic infections and increased physiological
demand during pregnancy [2]. In pregnancy, iron deficiency
anaemia is associated with poor birth outcomes such as increased
risk of still births, low birth weight infants, intrauterine growth
restriction and neonatal sepsis [3,4].
More recently, anaemia was also a common clinical finding in
HIV infected women and has been associated with advanced
disease. In Sub-Saharan Africa, a region most affected by the HIV
pandemic, anaemia in HIV infected women has been indepen-
dently associated with adverse maternal and fetal outcomes in
pregnancy [5–7]. In 2012, the Saving Mothers Report in South
Africa concluded that HIV infection (70%) and anaemia (30%)
were the commonest conditions among women who died during
pregnancy or in the puerperium [8]. Although not explored in the
Saving Mothers Report, through other studies the use of
antiretroviral drugs such as Zidovudine (ZDV) either for
prevention of mother to child transmission (MTCT) of HIV or
used in combination with other antiretrovirals have been
implicated in the development or increased severity of anaemia
[9]. A recent clinical trial across three Sub-Saharan African
countries demonstrated that women randomized to short or longer
ZDV containing regimens were at similar risk of severe anaemia
and the longer the duration of a triple antiretroviral (ARV)
regimen the greater the reduction in the incidence of anaemia
[10]. These findings are inconsistent with studies conducted in
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Malawi and Mozambique that implicated ZDV containing
regimens as risk for anaemia [11].
Zidovudine containing regimens as prophylaxis for PMTCT
remains the most affordable and cost-effective option in most Sub-
Saharan African countries with a high HIV disease burden. Yet,
not many studies have sought to confirm if anaemia, a potential
side effect of Zidovudine use, could be attributed to the HIV
disease stage itself and could be avoided if pregnant women in the
advanced stage of disease are treated with a triple antiretroviral
regimen.
We report the prevalence, type, severity and subsequent
incidence of anaemia in a cohort of HIV infected women during
pregnancy, within 72 hours post-delivery and 2 weeks post-
delivery in association with HIV disease stage (CD4 count) alone
or in relation to ARV prophylaxis or treatment. HIV positive
pregnant women in South Africa during the course of the
HPTN046 study were eligible for triple ARV (D4T/3TC/NVP) if
they were in the advanced stage of the disease (CD4,200) and
ZDV used as prophylaxis to prevent MTCT in women not
meeting the treatment criteria. We also describe the potential
impact of anaemia on maternal and infant birth outcomes.
Methods
Ethics Statement
This secondary data analysis study was reviewed and approved
by the Institutional Review Board of University of KwaZulu Natal.
Participant informed consent specific to this sub study was not
obtained; hence participant records were anonymized and de-
identified prior to analysis.
This study is a retrospective cohort data analysis of mother-
infant pairs who participated in the HPTN 046 Study (Clinical
Trials.gov. Identifier: NCT 00074412) conducted in Umlazi,
South Africa [12]. The HPTN046 Study was a Phase III
randomized controlled trial conducted in South Africa, Uganda,
Zimbabwe and Tanzania to determine the efficacy and safety of
an extended regimen of nevirapine in infants born to HIV-infected
women to prevent transmission of HIV through breastfeeding.
Further details of the study conduct and outcome measures have
previously been published and can also be accessed at www.
HPTN.org. Data for the South African cohort prior to
randomisation in the clinical trial were captured on site and
therefore readily available for this sub study analysis. For this
reason, other sites were not included.
The study was conducted at a clinical trial research facility
based at a tertiary hospital in Umlazi, South Africa. Umlazi is an
urban township with an antenatal HIV prevalence of 40%. HIV
positive pregnant women, 18 years or older, intending to
breastfeed, free from any serious medical complication and
residing in Umlazi were referred from the primary health care
clinics in Umlazi to the research facility.
The women initiated either ZDV prophylaxis or triple ARV
(D4T/3TC/NVP) at the primary health care clinic prior to being
referred for study participation at the clinical research site [13].
Women were enrolled at an average gestational age of 28 weeks
between February, 2007 and March, 2010. After enrollment, study
visits occurred within 72 hours post-delivery and at two, five and
six weeks, and at three, six, and 12 months postpartum. At each
visit a medical history and physical examination were completed.
HIV disease staging was completed using the WHO staging
system. A complete blood count (CBC) and CD4+ lymphocyte
count was obtained in a local laboratory (BARC, Johannesburg)
certified by the NIAID Division of AIDS Quality Assurance
Program. Haematological results were reported with age-related
reference intervals for the South African population. Evaluations
at delivery included birth outcomes, mode of delivery and
obstetrical complications. Clinical evaluations of the infant
included a physical examination and a CBC within 72 hours of
birth, two and five weeks of age and at subsequent follow-up visits
up to 18 months of age. This sub study utilised data obtained at
enrolment in pregnancy, within 72 hours of delivery and two
weeks post-delivery. Women also received the standard combina-
tion of micronutrient supplementation (iron, folate and multivita-
mins) during pregnancy [14].
Definitions. Anaemia in women was characterised hemoglo-
bin (Hb) levels below 11 g/dL and severity of Anaemia was graded
as follows: grade 1 or mild (9.5–10.5 g/dL), grade 2 or moderate
(8–9.4 g/dL), grade 3 or severe (6.5–7.9 g/dL) and grade 4 or life
threatening (,6.5 g/dL). Anaemia in the newborns was defined as
hemoglobin (Hb) levels below 13 g/dL. Severity of anaemia in the
newborns was graded as follows: grade 1 or mild (12–13 g/dL),
grade 2 or moderate (10–11.9 g/dL), grade 3 or severe (9–9.9 g/
dL) and grade 4 or life threatening (,9 g/dL).
Pre-existing cases of anaemia at baseline in pregnancy were
included in determining the prevalence of anaemia in pregnancy.
New cases of anaemia were labelled as incident anaemia in women
who first developed anaemia (Hb,11.0 g/dL) at delivery or 2
weeks post-delivery. Resolution of anaemia was defined as
recovery in Hb level to $11.0 g/dL at delivery or 2 weeks post-
delivery.
Post-hoc Power Estimation
If the proportions of pregnant women with a higher CD4 count
(.200 cells/mm3) receiving ZDV or D4T/3TC/NVP and who
have anaemia were 0.6 and 0.42 respectively then one would have
80% power to detect a difference between the two groups if there
were 200 women in the ZDV group and 100 women in the D4T/
3TC/NVP group. In the lower CD4 count group (,200 cells/
mm3), having 30 women per group would have 80% power to
detect a difference between the two groups if the proportions of
women with anaemia were 0.55 and 0.9, respectively.
Data were analysed using EpiInfo version 6.0 and SAS version
9.3. Maternal and infant characteristics were summarized using
means, proportions, and 95% confidence intervals where applica-
ble.
Relative risks and 95% confidence intervals were calculated to
determine risk factors for anaemia. P-values were calculated using
Fisher’s exact test or chi-square tests. Multivariable models were
fitted to determine adjusted relative risks using a generalised linear
approach with a log-binomial model. All variables were included
in the multivariable analysis.
Results
Four hundred and eight HIV positive pregnant women ranging
between 18 and 42 years were included in this analysis. The
majority (90.2%) was single mothers, 21.6% were primigravidae
and women were screened for anaemia at a median gestational age
of 32 weeks (IQR 30–35 weeks).
The mean Hb concentration was 10.6 g/dL at baseline and
262/408 (64.2%) women were diagnosed with anaemia (Hb,
11 g/dL) in pregnancy (prevalence), 48/146 (32.9%) subsequently
developed anaemia intrapartum or postpartum and 89/310
(28.7%) of all cases of anaemia remained unresolved by 2 weeks
post-delivery (Figure 1). A total number of 57 of the 408 (13.9%)
women enrolled in pregnancy were missed at delivery (n = 30) or 2
weeks post-delivery (n = 27).
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The median CD4 count among women with anaemia and
without anaemia was 320 (IQR 217–463) and 392 (IQR 285–546)
respectively. A significantly larger proportion of the 262 pregnant
women with anaemia (56/262) were in an advanced stage of HIV
disease (CD4,200) when compared to women without anaemia
(10/146) (21.4% vs 6.9%; p,0.001).
Anaemia was predominantly mild during pregnancy (80.9%)
and post-delivery (.75%), with the more severe cases of anaemia
(Grade 3 and 4) presenting in 3.5% and 3.4% of the women
immediately post-delivery and 2 weeks post-delivery respectively
(Table 1). Normocytic normochromic anaemia was most com-
monly diagnosed in pregnancy (82.8%), within 72 hours of
delivery (68.3%) and at 2 weeks postdelivery (62.9%). Further-
more, macrocytic anaemia also occurred in a third (30.4%) of the
women who presented with persistent anaemia at 2 weeks post-
delivery. Microcytic hypochromic anaemia remained least com-
mon in pregnancy (9.5%) and post-delivery (4.0–6.7%).
Approximately two thirds (268/408; 65.9%) of the study
population experienced some form of morbidity during pregnancy
and post-delivery, with urinary tract infections (94/407; 23.1%)
and abnormal vaginal discharge characteristic of vaginal infections
(80/407; 19.7%) being most commonly reported (Table 2).
Complications in pregnancy were reported in 177/261 (67.8%)
and 91/146 (62.3%) of women with and without anaemia
respectively (p = 0.28). Urinary tract infections were highly
common in women with anaemia, but not significantly higher
when compared to women without anaemia (RR 1.46 p = 0.07).
The median birth weight of infants born to the HIV positive
study population was 3.1 kg ranging from 1.2 to 4.5 kg. Twenty
five newborns (6.7%) were of low birth weight (,2.5 kg); 8/132
(6.1%) born to women without anaemia and 17/244 (7.0%)
women with anaemia (Table 2). Anaemia (Hb,13 g/dl) was more
than twice as common in infants born to women with anaemia
when compared to infants born to women without anaemia
(RR2.25; p = 0.09).
Among the 408 pregnant women screened for anaemia, 259
(63.5%) were receiving the ZDV regimen and 122 (29.9%) were
receiving the triple ARV regimen (D4T/3TC/NVP). Antiretro-
viral data was unavailable for 27 women, who were therefore
excluded from this particular analysis. Anaemia was more
common among women with a CD4,200 receiving ZDV
(75.9%) or triple ARV (91.2%) as compared to women with a
CD4.200 receiving ZDV (61.3%) or triple ARV (60.2%).
However, in a stratified analysis of women in the two categorical
HIV disease stage groups (CD4,200 and CD4.200) receiving
either ZDV or triple ARV regimen, the risk for anaemia was not
statistically significant for any particular group (Table 3).
In a univariate analysis, CD4 count and gravidity were
significant risk factors for anaemia in pregnancy, RR 1.41; 1.23–
1.61 (p,0.001) and 1.10; 1.01–1.18 (p = 0.02) respectively. After
adjusting for antiretroviral regimen, age and gravidity in a
multivariable analysis, only CD4 count remains a significant risk
factor for anaemia in pregnancy and post-delivery (Table 4).
Discussion
Almost two thirds (64%) of the HIV positive pregnant women in
our study were diagnosed with anaemia (HB,11 g/dL) in the 3rd
trimester of pregnancy, and subsequently an additional 11.8% of
the women were free from anaemia at screening but later
developed anaemia during pregnancy or post-delivery. In total,
75.8% of the HIV positive women presented with anaemia (Hb,
11 g/dL) during pregnancy and early postpartum. In a multivar-
iable analysis, after adjusting for the antiretroviral regimen (ZDV
or D4T/3TC/NVP), the lower CD4 count (,200 cells/mm3)
remained a significant risk factor for anaemia during pregnancy
and post-delivery. Moreover, having established that women in the
advanced stage of HIV disease (CD4,200 cells/mm3) are more
likely to be affected by anaemia in this study, we further report
that there was no evidence of any added risk for anaemia with
either of the ARV regimen (ZDV or the non ZDV containing
triple ARV regimen) in women with a higher CD4 count.
Our study is one of few reported cohort studies of anaemia in
HIV positive pregnant women. Similar to other reports, 60% of
the anaemia cases in our study resolved post-delivery and the
persistent anaemia cases post-delivery were more likely to have
Figure 1. Prevalence, incidence and recovery of anaemia in pregnancy, within 72 hours postpartum and day 14 postdelivery.
doi:10.1371/journal.pone.0106103.g001
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been moderate to severe microcytic hypochromic (iron deficiency)
anaemia at baseline in pregnancy [15]. While we can attribute the
resolution of anaemia to a combination of antiretroviral treatment
and reversion to a non-pregnant physiological state, the persistent
iron deficiency anaemia seems not to have been altered by
standard haematinic supplementation during pregnancy. Identi-
fied as a limitation in our study, the data for this analysis are
obtained at only 3 time points that includes 1 assessment only in
the 3rd trimester of pregnancy. Adherence to haematinic
supplementation or duration of antiretroviral treatment was
therefore not measured.
According to the WHO classification, the high occurrence of
anaemia (HB,11 g/dL) in our cohort of HIV infected pregnant
women (75.8%) would be considered a severe public health
problem [16]. Although we had not sought to determine the
independent role of HIV infection in the development of the high
prevalence of anaemia, other studies in South Africa with an
antenatal HIV prevalence of 30% and countries similarly affected
by the HIV pandemic have confirmed that HIV infected adults
are more likely to develop anaemia [17]. In the context of HIV
infection, anaemia and iron deficiency have been often implicated
as independent markers of HIV disease progression and mortality
[18–19]. Further evidence of anaemia as a severe public health
Table 1. Anaemia in pregnancy, within 72 hours of delivery and 2 weeks post delivery.
Pregnancy N = 408 0–72 Hours Delivery N = 378 2 weeks Post Delivery N = 351
Hb (g/dL)
Mean (Range) 10.6 (7.4–13.9) 10.4 (5.8–14.7) 11.8 (6.9–15.9)
Median (IQR) 10.6 (9.9–11.3) 10.9 (10.0–11.6) 11.9 (10.9–12.8)
Prevalence of Anaemia (Hb,11 g/dL) n(%) 262 (64.2) 202 (53.4) 89 (25.4)
Severity of Anaemia n(%)
Grade 1 mild (9.5–10.5 g/dL) 212 (80.9) 156 (77.2) 71 (79.8)
Grade 2 moderate (8.0–9.4 g/dL) 47 (17.9) 39 (19.3) 15 (16.8)
Grade 3 severe (6.5–7.9 g/dL) 3 (1.2) 6 (3.0) 3 (3.4)
Grade 4 life threatening (,6.5 g/dL) 0 1 (0.5) 0
*Types of Anaemia n(%)
Microcytic 25 (9.5) 8 (4.0) 6 (6.7)
Macrocytic 20 (7.7) 56 (27.7) 27 (30.4)
Normocytic 217 (82.8) 138 (68.3) 56 (62.9)
*Microcytic Anaemia: Mean Corpuscular Volume (MCV) ,83fL.
Normocytic Anaemia: Mean Corpuscular Volume (MCV) 83–101 fL.
Macrocytic Anaemia: Mean Corpuscular Volume (MCV) .101 fL.
doi:10.1371/journal.pone.0106103.t001
Table 2. Obstetric and Infant Outcomes in Association with Anaemia in Pregnancy.
Total No Anaemia (Hb$11 g/dL) Anaemia (Hb,11 g/dL) RR (95%CI) p Value
n = 408 n = 146 n = 262
Complications in Pregnancy n (%) 268/407 (65.9) 91/146 (62.3) 177/261 (67.8) 1.09 (0.94–1.27) p = 0.28
Antepartum Haemorrhage 6/407 (1.5) 2/146 (1.4) 4/261 (1.5) 1.12 (0.21–6.03) p = 1.00
PreEclampsia 22/407 (5.4) 8/146 (5.5) 14/261 (5.4) 0.98 (0.42–2.28) p = 1.00
Abnormal Vaginal Discharge/Infection 80/407 (19.7) 39/146 (26.7) 41/261 (15.7) 0.59 (0.40–0.87) p = 0.01
Urinary Tract Infections 94/407 (23.1) 26/146 (17.8) 68/261 (26.1) 1.46 (0.98–2.19) p = 0.07
Genital Warts 20/407 (4.9) 6/146 (4.1) 14/261 (5.4) 1.31 (0.51–3.32) p = 0.64
Preterm Delivery 53/405 (13.1) 21/146 (14.4) 32/259 (12.4) 0.86 (0.51–1.43) p = 0.65
Infant Outcomes
Live birth n(%)







0.99 (0.97–1.02) p = 1.00
p = 0.72
Birth weight ,2.5 kg 25/376 (6.7) 8/132 (6.1) 17/244 (6.9) 1.15 (0.51–2.59) p = 0.83
Infant Anaemia ,13 g/dl n (%) 26/375 (6.9) 5/131 (3.8) 21/244 (8.6) 2.25 (0.87–5.84) p = 0.09
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problem in South Africa is manifested in the recent South African
maternal mortality report in which 9.2% of the maternal deaths
were attributed to severe anaemia [8]. The report provides further
evidence of severe anaemia being the more common cause of
death among HIV infected women who were diagnosed with
AIDS and did not receive ARV treatment (10%) as compared to
women who were not eligible for ART (7%). Another study
showed that women with severe anaemia at baseline had a 13
times greater risk of death during the first year of ART, further
confirming that anaemia is strongly associated with HIV disease
progression [20]. However whether anaemia is an outcome of or a
cause of increased HIV virulence and immunological degradation
requires further investigation.
Antiretroviral use, particularly ZDV has frequently and more
recently been implicated in the development of anaemia in women
and in their newborns [21]. Our study has not demonstrated such
an association between either of the ARV regimens. In fact similar
to a study in Tanzania, antiretroviral use (ZDV or D4T/3TC/
NVP) in pregnancy may have prevented progression of anaemia as
shown by the high resolution rate of anaemia (40%) and the higher
median Hb level immediately postpartum and 14 day post-
delivery [20]. Unlike the Tanzanian study though, most of the
anaemia in our population were non-iron deficiency anaemia and
more likely HIV associated with chronic infection and therefore
resolving more rapidly with the use of ARV’s in addition to the
standard iron and folic acid micronutrient supplementation in
pregnancy. In a study from Malawi, 16% of women with HIV had
anaemia due to iron deficiency [22]. Only 14.5% of anaemia cases
in our South African study population were related to iron
deficiency, confirming that normocytic normochromic anaemia of
chronic inflammation (due to reduced erythropoietin production)
was the biggest contributor.
There were no maternal deaths in our cohort and neither was
there a significant association between anaemia and adverse
pregnancy outcomes. However, urinary tract infections were
significantly more common among women with anaemia. Studies
have implicated urinary tract infections in pregnancy as a cause of
anaemia, women in our study who presented with low Hb levels at
baseline were predisposed to urinary tract infections [23]. Other
pregnancy complications and adverse pregnancy outcomes asso-
ciated with anaemia such as pre-eclampsia, preterm labour, and
Table 3. Anaemia in Association with Antiretroviral Use and HIV Disease Stage (CD4 Count ,200 cells/mm3).
CD4 #200 cells/mm3 CD4 .200 cells/mm3
ZDV D4T/3TC/NVP ZDV D4T/3TC/NVP
n/N (%) n/N (%) RR (95% CI) p-value n/N (%) n/N (%)
RR (95% CI) p-
value
Anaemia in pregnancy 22/29 (75.9) 31/34 (91.2) 0.83 (0.66; 1.05) 0.17 141/230 (61.3) 53/88 (60.2) 1.02 (0.83; 1.24) 0.90
Anaemia ,72 hours after
delivery
22/28 (78.6) 21/34 (61.8) 1.27 (0.92; 1.77) 0.18 116/227 (51.1) 41/86 (47.7) 1.07 (0.83; 1.38) 0.61
Anaemia 2 weeks post
delivery
12/24 (50.0) 12/34 (35.3) 1.42 (0.77; 2.60) 0.29 45/211 (21.3) 20/82 (24.4) 0.87 (0.55; 1.39) 0.64
Infant Anaemia At Birth 7/28 (25.0) 1/34 (2.9) 8.5 (1.11; 65.0) 15/227 (6.6) 3/86 (3.5) 1.89 (0.56; 6.38)
doi:10.1371/journal.pone.0106103.t003
Table 4. Association between HIV Disease Stage and Anaemia in Pregnancy and Postdelivery.
Univariate analysis Multivariable analysis
Anaemia in pregnancy RR (95% CI) p-value RR (95% CI) p-value
ART 0.91 (0.79; 1.06) 0.25 0.96 (0.85; 1.09) 0.54
CD4 count (#200 vs .200) 1.41 (1.23; 1.61) ,0.001 1.23 (1.08; 1.39) 0.001
Age 1.01 (0.99; 1.02) 0.23 0.99 (0.98; 1.01) 0.50
Gravidity 1.10 (1.01; 1.18) 0.02 1.07 (0.98; 1.16) 0.15
Anaemia ,72 hours after delivery
ART 1.05 (0.85; 1.29) 0.66 1.14 (0.93; 1.40) 0.22
CD4 count (#200 vs .200) 1.38 (1.13; 1.68) 0.002 1.44 (1.17; 1.78) 0.001
Age 1.00 (0.99; 1.02) 0.64 1.00 (0.98; 1.03) 0.65
Gravidity 0.95 (0.86; 1.06) 0.38 0.93 (0.83; 1.05) 0.24
Anaemia 2 weeks post delivery
ART 1.05 (0.85; 1.29) 0.66 1.14 (0.93; 1.40) 0.22
CD4 count (#200 vs .200) 1.38 (1.13; 1.68) 0.002 1.44 (1.17; 1.78) 0.001
Age 1.00 (0.99; 1.02) 0.64 1.00 (0.98; 1.03) 0.65
Gravidity 0.95 (0.86; 1.06) 0.38 0.93 (0.83; 1.05) 0.24
doi:10.1371/journal.pone.0106103.t004
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low birth weight in other studies were not evidently associated with
anaemia in our HIV infected pregnant population [24].
Although the association was not statistically significant
(p = 0.09), infants born to mothers who presented with anaemia
in pregnancy were twice more likely to be anemic (8.6% vs 3.8%)
at birth. While evidence in some studies suggests that use of
antiretrovirals in pregnancy were associated with haematological
disorders in the newborns, our study also demonstrated a higher
trend among infants born to mothers with CD4,200 and
receiving ZDV but not among other mothers receiving triple
ARVs [25–26]. Although in more recent studies, when HAART
was rapidly becoming the standard of care for pregnant women,
anaemia (grade 2 toxicity) was reported in almost half of the infant
population and was most severe by 2 weeks of age [27–28].
Further studies are needed to explore the effect of ARVS on the
neonatal outcomes.
A limitation of this study was that the sample was relatively
small and was only powered to detect large differences between
women with aneamia and without.
In conclusion, anaemia was most common among women in the
advanced stage of HIV infection. There was no evidence of an
association between ZDV or triple ARVs and anaemia. Antiret-
roviral treatment together with standard haematinic therapy could
have contributed to the rapid resolution of anaemia post-delivery.
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